Carsgen announces preliminary clinical data for allogeneic bcma car-t ct0596, demonstrating favorable safety and efficacy

Shanghai , may 11, 2025 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on developing innovative car t-cell therapies, announces preliminary clinical data for ct0596, an allogeneic bcma-targeted car-t developed using the thank-u plus™ platform. ct0596 is currently being evaluated in an early exploratory clinical study for relapsed/refractory multiple myeloma (r/r mm) or relapsed/refractory plasma cell leukemia (r/r pcl) to assess its safety, and preliminary efficacy.
CAR Ratings Summary
CAR Quant Ranking